Tirzepatide
The sentences below are limited to one FDA page opened for this draft.
What the opened sources say
Section titled “What the opened sources say”- FDA names tirzepatide among GLP-1 receptor agonist drugs for which people seek unapproved versions that are not reviewed for safety, effectiveness, and quality before marketing.
- As of 31 May 2026, FDA says it had received more than 730 adverse-event reports associated with compounded tirzepatide, with the same caveats it gives for compounded semaglutide: causality is not always clear, and underreporting is likely.
- FDA describes fraudulent compounded tirzepatide whose labels name pharmacies that did not compound the product. It says it is aware of one adverse-event report for such a product, with redness, swelling, pain, and a red lump at the injection site.
- FDA includes tirzepatide in the warning about unapproved drugs sold with research-use or not-for-human-consumption labels and dosing instructions.
Not stated here
Section titled “Not stated here”FDA discusses tirzepatide alongside semaglutide as a GLP-1 drug people seek in unapproved versions. This page does not state whether the approved products are single or dual agonists.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
Referenced by
A link from another wiki page is not evidence. Facts should point at the sources above.